"The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness."
"In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight -- about 25 pounds on average -- over more than 16 months."
"Both the Lilly and Novo Nordisk pills resulted in less weight loss than the average achieved with Lilly's injectable Zepbound, which results in a 21% average weight loss, or Novo Nordisk's injectable Wegovy, which averages about 15%."
Eli Lilly's new weight-loss pill, orforglipron, received FDA approval and will be marketed as Foundayo. This GLP-1 drug mimics a natural hormone to control appetite. It is expected to be available for insured patients at $25 per month, while cash prices range from $149 to $349. In clinical trials, participants lost an average of 11.2% of their body weight over 16 months. This new pill offers convenience compared to injectable alternatives, although weight loss results are lower than those from injectable medications.
Read at ABC7 New York
Unable to calculate read time
Collection
[
|
...
]